Sierra Oncology, Inc. SRRA
54.99 0.00 (+0.00%)
Apr 24, 2025, 3:47 PM EDT
54.98 Day range 55.01
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 55.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 4
- 2 months ago 5
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.95 | -1.02 – -0.88 | -1.67 | +43.1% | 0 | 0.0% | 2 |
| Next quarter | -1.09 | -1.17 – -1.02 | -2.10 | +48.1% | 0 | 0.0% | 2 |
| Current year | -4.79 | -5.91 – -3.90 | -7.14 | +32.9% | 0 | 0.0% | 4 |
| Next year | -3.86 | -4.41 – -3.29 | -4.79 | +19.4% | 20.58M | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 14, 2022 | Jefferies | Downgrade | Buy | Hold |
| Apr 14, 2022 | Oppenheimer | Downgrade | Outperform | Perform |
| Apr 13, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 14, 2022 | Oppenheimer | Maintained | — | Outperform |
| Jan 31, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 30, 2021 | Cantor Fitzgerald | Maintained | — | Overweight |
| Nov 5, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 27, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 25, 2020 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 25, 2020 | Oppenheimer | Initiated | — | Outperform |
| Nov 25, 2020 | SunTrust Robinson Humphrey | Upgrade | Hold | Buy |
| Nov 25, 2020 | Wedbush | Upgrade | Neutral | Outperform |